Back to Search
KENT KESTER, M.D.
M.D.
Infectious Disease Physician
NPI: 1649250622IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
D0036095(MD)MD040278E(PA)
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
D0036095(MD)MD040278E(PA)
Education
JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY
Class of 1986
Research & Publications (20)
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
PMID 19569965·J Infect Dis·2009
3-trial
Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
PMID 18387719·Vaccine·2008
3-trial
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.
PMID 17574311·Vaccine·2007
3-trial
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
PMID 11170991·J Infect Dis·2001
3-trial
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.
PMID 19649245·PLoS One·2009
3-trial
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
PMID 19390585·PLoS One·2009
3-trial
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
PMID 19276646·Hum Vaccin·2009
4-observational
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.
PMID 18455276·Vaccine·2008
7-preclinical
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
PMID 16388879·Vaccine·2007
3-trial
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
PMID 17442466·Vaccine·2007
3-trial
Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
PMID 16911849·Vaccine·2006
4-observational
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
PMID 16904798·Vaccine·2006
7-preclinical
Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
PMID 16837726·Am J Trop Med Hyg·2006
3-trial
Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria.
PMID 16988231·Infect Immun·2006
8-other
Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
PMID 16574282·Vaccine·2006
7-preclinical
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
PMID 16356603·Vaccine·2006
3-trial
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
PMID 15964483·Vaccine·2005
3-trial
Investigating the effect of the zwitterion/lactone equilibrium of rhodamine B on the cybotactic region of the acetonitrile/scCO2 cosolvent.
PMID 16833502·J Phys Chem A·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 22 S GREENE ST
BALTIMORE, MD 21201 - Phone
- (410) 328-6704
Quick Facts
- NPI
- 1649250622
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile